CalciMedica (NASDAQ:CALC) Stock Rating Lowered by Wall Street Zen

CalciMedica (NASDAQ:CALC) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research analysts also recently issued reports on the stock. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Guggenheim started coverage on CalciMedica in a research report on Thursday, August 20th. They set a “buy” rating on the stock. Finally, UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $50.00.

CalciMedica Price Performance

CALC opened at $1.98 on Friday. The business has a 50 day moving average of $3.31 and a 200-day moving average of $3.44. The stock has a market capitalization of $13.52 million, a price-to-earnings ratio of -0.29 and a beta of 0.83. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67. CalciMedica has a 1-year low of $1.91 and a 1-year high of $36.00.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. As a group, sell-side analysts anticipate that CalciMedica will post -5.25 earnings per share for the current year.

Insider Activity

In other CalciMedica news, Director Fred A. Middleton acquired 49,794 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The stock was bought at an average cost of $4.00 per share, with a total value of $199,176.00. Following the acquisition, the director owned 212,654 shares of the company’s stock, valued at approximately $850,616. The trade was a 30.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 28.25% of the company’s stock.

Institutional Trading of CalciMedica

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in CalciMedica during the fourth quarter worth about $127,000. Cetera Investment Advisers boosted its holdings in CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of CalciMedica in the 4th quarter valued at approximately $506,000. Renaissance Technologies LLC grew its stake in shares of CalciMedica by 26.1% in the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares in the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.